178 related articles for article (PubMed ID: 18514790)
1. TGFB1 single-nucleotide polymorphisms are associated with adverse quality of life in prostate cancer patients treated with radiotherapy. In regard to Peters et al. (Int J Radiat Oncol Biol Phys 2008;70:752-759).
Langsenlehner T; Kapp KS; Langsenlehner U
Int J Radiat Oncol Biol Phys; 2008 Jul; 71(3):960; author reply 960-1. PubMed ID: 18514790
[No Abstract] [Full Text] [Related]
2. TGFB1 single nucleotide polymorphisms are associated with adverse quality of life in prostate cancer patients treated with radiotherapy.
Peters CA; Stock RG; Cesaretti JA; Atencio DP; Peters S; Burri RJ; Stone NN; Ostrer H; Rosenstein BS
Int J Radiat Oncol Biol Phys; 2008 Mar; 70(3):752-9. PubMed ID: 17689884
[TBL] [Abstract][Full Text] [Related]
3. In regard to Fiorino et al.: Rectal dose-volume constraints in high-dose radiotherapy of localized prostate cancer (Int J Radiat Oncol Biol Phys 2003;57:953-962).
Bauman G; Rodrigues G
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):912-4; author reply 914-5. PubMed ID: 15183497
[No Abstract] [Full Text] [Related]
4. The need and prospect of individualized external beam radiotherapy dose escalation beyond 80 gy to treat prostate cancer: in regard to Eade et al. (Int J. Radiat. Oncol. Biol. Phys. 2007;68:682-689).
Cheung MR
Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):645; author reply 645-6. PubMed ID: 18207039
[No Abstract] [Full Text] [Related]
5. Association of single nucleotide polymorphisms in SOD2, XRCC1 and XRCC3 with susceptibility for the development of adverse effects resulting from radiotherapy for prostate cancer.
Burri RJ; Stock RG; Cesaretti JA; Atencio DP; Peters S; Peters CA; Fan G; Stone NN; Ostrer H; Rosenstein BS
Radiat Res; 2008 Jul; 170(1):49-59. PubMed ID: 18582155
[TBL] [Abstract][Full Text] [Related]
6. Radiation-induced sequelae measured by means of lymphocyte apoptosis: importance of certain single nucleotide polymorphisms: in regard to Schnarr et al. (Int J Radiat Oncol Biol Phys 2009).
Azria D; Ozsahin M; Rosenstein B
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1275; author reply 1275-6. PubMed ID: 19857791
[No Abstract] [Full Text] [Related]
7. Transperineal injection of hyaluronic acid in anterior perirectal fat to decrease rectal toxicity from radiation delivered with intensity-modulated brachytherapy or EBRT for prostate cancer patients: in regard to Prada et al. (Int J Radiat Oncol Biol Phys 2007;69:95-102.).
Vordermark D; Guckenberger M; Baier K; Markert K
Int J Radiat Oncol Biol Phys; 2008 May; 71(1):316-7. PubMed ID: 18406899
[No Abstract] [Full Text] [Related]
8. CTV margins in prostate cancer irradiation. In regard to Teh et al.: IMRT for prostate cancer: defining target volume based on correlated pathologic volume of disease (Int J Radiat Oncol Biol Phys 2003;56:184-191).
Macias V
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):320-1; author reply 321-2. PubMed ID: 15093933
[No Abstract] [Full Text] [Related]
9. Determination of TGF-beta1 plasma levels: In regard to Anscher et al. (Int J Radiat Oncol Biol Phys 2003;56: 988-995) and de Jaeger et al (Int J Radiat Oncol Biol Phys 2004;58: 1378-1387).
Barthelemy-Brichant N
Int J Radiat Oncol Biol Phys; 2004 Nov; 60(4):1339; author reply 1339-40. PubMed ID: 15519811
[No Abstract] [Full Text] [Related]
10. In regard to Trofimov et al.: Radiotherapy treatment of early-stage prostate cancer with IMRT and protons: a treatment planning comparison (Int J Radiat Oncol Biol Phys 2007;69:444-453).
Albertini F; Lomax AJ; Hug EB
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1333-4; author reply 1334-5. PubMed ID: 17967323
[No Abstract] [Full Text] [Related]
11. Volumetric modulated arc therapy for delivery of prostate radiotherapy: in regard to Palma et al. (Int J Radiat Oncol Biol Phys 2008;70:996-1001).
Ost P; Fonteyne V; De Neve W; De Gersem W; De Wagter C; Vandecasteele K; Duprez F; De Meerleer G
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1286; author reply 1287. PubMed ID: 19251105
[No Abstract] [Full Text] [Related]
12. Lack of association of transforming growth factor-beta1 polymorphisms and haplotypes with prostate cancer risk in the prostate, lung, colorectal, and ovarian trial.
Kang D; Lee KM; Park SK; Berndt SI; Reding D; Chatterjee N; Welch R; Chanock S; Huang WY; Hayes RB
Cancer Epidemiol Biomarkers Prev; 2007 Jun; 16(6):1303-5. PubMed ID: 17548703
[No Abstract] [Full Text] [Related]
13. Response to "Intraoperative radiotherapy during radical prostatectomy for locally advanced prostate cancer: technical and dosimetric aspects" (Int J Radiat Oncol Biol Phys 2009; in press).
Thoms J; Bristow R; Warde P; Supiot S
Int J Radiat Oncol Biol Phys; 2010 Mar; 76(4):1277; author reply 1277. PubMed ID: 20206029
[No Abstract] [Full Text] [Related]
14. Androgen Deprivation (AD) among low-risk and intermediate-risk prostate cancer patients: in regard to Ciezki et al. (Int J Radiat Oncol Biol Phys 2004;60:1347-1350).
Oton CA
Int J Radiat Oncol Biol Phys; 2005 May; 62(1):291-2; author reply 292. PubMed ID: 15850937
[No Abstract] [Full Text] [Related]
15. Genetic susceptibility of epidermal growth factor +61A>G and transforming growth factor beta1 -509C>T gene polymorphisms with gallbladder cancer.
Vishnoi M; Pandey SN; Modi DR; Kumar A; Mittal B
Hum Immunol; 2008 Jun; 69(6):360-7. PubMed ID: 18571008
[TBL] [Abstract][Full Text] [Related]
16. In regard to Kupelian et al.: Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seed/external beam radiotherapy for stage T1-T2 prostate cancer (Int J Radiat Oncol Biol Phys 2004;58:25-33).
Halperin RM
Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):631-2; author reply 632. PubMed ID: 15667989
[No Abstract] [Full Text] [Related]
17. PSA failure and the risk of death in prostate cancer patients treated with radiotherapy: in regard to Kwan et al. (Int J Radiat Oncol Biol Phys 2004;60:1040-1046).
Williams S
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(4):1253-4; author reply 1254. PubMed ID: 15990030
[No Abstract] [Full Text] [Related]
18. Comment on dose escalation and biochemical failure in prostate cancer: in regard to Kuban et al. (Int J Radiat Oncol Biol Phys 2008;70:67-74).
Schulz RJ; Kagan AR
Int J Radiat Oncol Biol Phys; 2008 Jul; 71(4):1288; author reply 1288-9. PubMed ID: 18572089
[No Abstract] [Full Text] [Related]
19. Commentary on dose escalation and biochemical failure in prostate cancer: in regard to Eade et al. (Int. J. Radiat. Oncol. Biol. Phys. 2007;68:682-689).
Schulz RJ; Kagan AR
Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):645; author reply 645-6. PubMed ID: 18207038
[No Abstract] [Full Text] [Related]
20. In regards to Thames et al.: increasing external beam dose for T1-T2 prostate cancer: effect on risk groups. (Int J Radiat Oncol Biol Phys 2006;65:975-981).
Pickles T; Williams SG
Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):318-9; author reply 319. PubMed ID: 17189080
[No Abstract] [Full Text] [Related]
[Next] [New Search]
